Compare BioNTech SE - ADR (BNTX) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Lemonade Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Lemonade Inc trades at $51.51 (market cap $4.09B). The key difference: BioNTech SE - ADR is far larger — about 5.7× Lemonade Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | LMND | |
|---|---|---|
Market Cap | $23.31B | $4.09B |
Sector | Health | Financials |
52-Week High | $119.34 | $96.57 |
52-Week Low | $83.89 | $47.38 |
Enterprise Value | $6.60B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Lemonade (LMND) trades at $51.63, down 1.99% on the day, with a bearish technical signal from moving averages. Revenue growth is strong, reaching $737.9M in 2025, but the company remains unprofitable with a net income margin of -14.19%. Recent Q2 2026 earnings beat expectations, and the company targets positive adjusted EBITDA by Q4 2026, yet the stock faces selling pressure amid valuation concerns.
The outlook hinges on Lemonade's path to profitability; achieving its EBITDA target could drive upside toward the $58 consensus price target. Key risks include persistent losses, competitive pressures, and execution challenges in scaling its AI-driven insurance model. Investor sentiment is divided, reflecting the high-growth but high-burn profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
